Investors

Welcome on board!

Company overview

Pharnext is an advanced clinical-stage biopharmaceutical company committed to developing novel therapeutics for neurodegenerative diseases that currently lack curative and/or disease-modifying.

Pharnext has two lead products in clinical development. PXT3003 completed an international Phase III trial with positive topline results for the treatment of Charcot-Marie-Tooth disease type 1A (‘CMT1A’) and benefits from orphan drug status in Europe and the United States. An international pivotal Phase III study of PXT3003 in CMT1A, the PREMIER trial, is currently ongoing. PXT864 has generated encouraging Phase II results in Alzheimer’s disease and will be advanced through partnerships. Both of Pharnext’s lead assets originated from the Pleotherapy R&D approach.

˪ Disclosure of the total number of voting rights and shares composing the share capital

Date

Total number of shares composing the share capital

July 15, 2022

1,345,066,853  (1)

(1)    This table will be subject to a monthly update of the number of shares issued from the convertible bond program announced on June 7, 2021, with Global Tech Opportunities 13, and detailed in follow-up tables available on the website https://equityline.vox-aequitas.com/pharnext

˪ Stock information

Stock Market

Euronext Growth Paris

Mnemo

ALPHA

Bloomberg

ALPHA/FR – Reuters: ALPHA.PA

ISIN Code


FR0011191287

Closing date


31 December

First day of trading


18 July 2016

Number of shares

See table above

Indices


EnterNext© PEA-PME 150,

Euronext Growth All-Share, Next Biotech, PEA

Liquidity contract


Kepler Cheuvreux

Eligible to PEA-PME (French fiscal advantage)

Share price


˪ Analysts coverage

The analysts listed on the right follow PHARNEXT. Any opinions, estimates or forecasts made by these analysts regarding PHARNEXT are individual and do not represent opinions, forecasts or predictions of PHARNEXT's management. PHARNEXT does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. Requests for copies of analyst reports should be directly addressed to the above-mentioned analyst and institution.

Kepler Cheuvreux : Damien Choplain - email
Gilbert Dupont : Guillaume Cuvillier - email
Edison Group : Jyoti Prakash - email

General meeting (only available in French)
Contact
˪ For investors
Pharnext Headquarters
Pharnext

46 Rue Saint-Lazare

75009 Paris, France

+33 (0)1 41 09 22 30

inverstors@pharnext.com
International
Consilium Strategic Communications

Mary-Jane Elliott
Sukaina Virji
Alexandra Harrison

pharnext@consilium-comms.com
France
Actifin France

Ghislaine Gasparetto

+33 (0)6 21 10 49 24

ggasparetto@actifin.fr
Contact
˪ For media
Pharnext Headquarters
Pharnext

46 Rue Saint-Lazare

75009 Paris

+33 (0)1 41 09 22 30

contact@pharnext.com
France
Ulysse Communication

Bruno Arabian

barabian@ulysse-communication.com
International
Consilium Strategic Communications

Mary-Jane Elliott
Sukaina Virji
Alexandra Harrison

pharnext@consilium-comms.com
Next step
Home